Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide.
Gómez-Rangel
J David
JD
Ruiz-Delgado
Guillermo J
GJ
Ruiz-Argüelles
Guillermo J
GJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001853:Bone Marrow / Q000002:abnormalities; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000473:pathology; D004347:Drug Interactions; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D013792:Thalidomide / Q000009:adverse effects; D014182:Transplantation, Autologous
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D013792:Thalidomide; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a